{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,12,30]],"date-time":"2025-12-30T08:51:56Z","timestamp":1767084716033,"version":"3.41.0"},"reference-count":59,"publisher":"Springer Science and Business Media LLC","issue":"7","license":[{"start":{"date-parts":[[2025,1,26]],"date-time":"2025-01-26T00:00:00Z","timestamp":1737849600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2025,1,26]],"date-time":"2025-01-26T00:00:00Z","timestamp":1737849600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"funder":[{"DOI":"10.13039\/501100002426","name":"Fondazione Telethon","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100002426","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100003407","name":"Ministero dell&apos;Istruzione, dell&apos;Universit\u00e0 e della Ricerca","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100003407","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100004462","name":"Consiglio Nazionale delle Ricerche","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100004462","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Mol Psychiatry"],"published-print":{"date-parts":[[2025,7]]},"DOI":"10.1038\/s41380-025-02904-6","type":"journal-article","created":{"date-parts":[[2025,1,26]],"date-time":"2025-01-26T10:52:06Z","timestamp":1737888726000},"page":"2980-2993","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":1,"title":["D1 dopamine receptor antagonists as a new therapeutic strategy to treat autistic-like behaviours in lysosomal storage disorders"],"prefix":"10.1038","volume":"30","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-2741-6837","authenticated-orcid":false,"given":"Maria","family":"De Risi","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Lorenzo","family":"Cusimano","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0009-0004-4660-7251","authenticated-orcid":false,"given":"Xabier","family":"Bujanda Cundin","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mariateresa","family":"Pizzo","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ylenia","family":"Gigante","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0009-0008-9637-7174","authenticated-orcid":false,"given":"Mariagrazia","family":"Monaco","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Chiara","family":"Di Eugenio","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0220-2864","authenticated-orcid":false,"given":"Elvira","family":"De Leonibus","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2025,1,26]]},"reference":[{"key":"2904_CR1","doi-asserted-by":"crossref","first-page":"471","DOI":"10.1146\/annurev-med-122313-085916","volume":"66","author":"G Parenti","year":"2015","unstructured":"Parenti G, Andria G, Ballabio A. Lysosomal storage diseases: from pathophysiology to therapy. Annu Rev Med. 2015;66:471\u201386.","journal-title":"Annu Rev Med"},{"key":"2904_CR2","doi-asserted-by":"crossref","first-page":"876","DOI":"10.1002\/ana.22092","volume":"68","author":"MJ Valstar","year":"2010","unstructured":"Valstar MJ, Neijs S, Bruggenwirth HT, Olmer R, Ruijter GJG, Wevers RA, et al. Mucopolysaccharidosis type IIIA: clinical spectrum and genotype-phenotype correlations. Ann Neurol. 2010;68:876\u201387.","journal-title":"Ann Neurol"},{"key":"2904_CR3","doi-asserted-by":"crossref","first-page":"277","DOI":"10.1146\/annurev-neuro-070815-014031","volume":"39","author":"A Fraldi","year":"2016","unstructured":"Fraldi A, Klein AD, Medina DL, Settembre C. Brain disorders due to lysosomal dysfunction. Annu Rev Neurosci. 2016;39:277\u201395.","journal-title":"Annu Rev Neurosci"},{"key":"2904_CR4","doi-asserted-by":"crossref","first-page":"41","DOI":"10.1016\/j.ymgmr.2016.01.003","volume":"6","author":"E Shapiro","year":"2016","unstructured":"Shapiro E, King K, Ahmed A, Rudser K, Rumsey R, Yund B, et al. The neurobehavioral phenotype in mucopolysaccharidosis Type IIIB: an exploratory study. Mol Genet Metab Reports. 2016;6:41\u201347.","journal-title":"Mol Genet Metab Reports"},{"key":"2904_CR5","doi-asserted-by":"crossref","first-page":"3620","DOI":"10.1007\/s10803-017-3262-6","volume":"47","author":"C Wolfenden","year":"2017","unstructured":"Wolfenden C, Wittkowski A, Hare DJ. Symptoms of autism spectrum disorder (ASD) in individuals with mucopolysaccharide disease type III (Sanfilippo syndrome): a systematic review. J Autism Dev Disord. 2017;47:3620\u201333.","journal-title":"J Autism Dev Disord"},{"key":"2904_CR6","doi-asserted-by":"crossref","first-page":"1147","DOI":"10.1016\/j.jpeds.2014.01.007","volume":"164","author":"RK Rumsey","year":"2014","unstructured":"Rumsey RK, Rudser K, Delaney K, Potegal M, Whitley CB, Shapiro E. Acquired autistic behaviors in children with mucopolysaccharidosis type IIIA. J Pediatr. 2014;164:1147\u201351.","journal-title":"J Pediatr"},{"key":"2904_CR7","doi-asserted-by":"crossref","first-page":"462","DOI":"10.1111\/apa.12169","volume":"102","author":"FA Wijburg","year":"2013","unstructured":"Wijburg FA, W\u0229grzyn G, Burton BK, Tylki-Szyma\u0144ska A. Mucopolysaccharidosis type III (Sanfilippo syndrome) and misdiagnosis of idiopathic developmental delay, attention deficit\/hyperactivity disorder or autism spectrum disorder. Acta Paediatr Int J Paediatr. 2013;102:462\u201370.","journal-title":"Acta Paediatr Int J Paediatr"},{"key":"2904_CR8","first-page":"75","volume":"39","author":"A Lehtonen","year":"2018","unstructured":"Lehtonen A, Rust S, Jones S, Brown R, Hare D. Social functioning and behaviour in mucopolysaccharidosis IH [Hurlers syndrome]. JIMD Rep. 2018;39:75\u201381.","journal-title":"JIMD Rep"},{"key":"2904_CR9","doi-asserted-by":"crossref","first-page":"e1258","DOI":"10.1542\/peds.2010-1274","volume":"127","author":"JB Holt","year":"2011","unstructured":"Holt JB, Poe MD, Escolar ML. Natural progression of neurological disease in mucopolysaccharidosis type II. Pediatrics. 2011;127:e1258\u201365.","journal-title":"Pediatrics"},{"key":"2904_CR10","doi-asserted-by":"crossref","DOI":"10.1136\/bcr.07.2008.0480","volume":"2009","author":"P Santosh","year":"2009","unstructured":"Santosh P, Parker JR, Jones L. Psychopharmacological treatment of behavioural problems in Sanfilippo syndrome. BMJ Case Rep. 2009;2009:bcr07.2008.0480.","journal-title":"BMJ Case Rep"},{"key":"2904_CR11","doi-asserted-by":"crossref","first-page":"275","DOI":"10.1080\/13668250903070891","volume":"34","author":"MC Tchan","year":"2009","unstructured":"Tchan MC, Sillence D. Extrapyramidal symptoms and medication use in Mucopolysaccharidosis type III. J Intellect Dev Disabil. 2009;34:275\u20139.","journal-title":"J Intellect Dev Disabil"},{"key":"2904_CR12","doi-asserted-by":"crossref","first-page":"156","DOI":"10.1016\/j.braindev.2008.12.010","volume":"32","author":"S Kalkan Ucar","year":"2010","unstructured":"Kalkan Ucar S, Ozbaran B, Demiral N, Yuncu Z, Erermis S, Coker M. Clinical overview of children with mucopolysaccharidosis type III A and effect of Risperidone treatment on children and their mothers psychological status. Brain Dev. 2010;32:156\u201361.","journal-title":"Brain Dev"},{"key":"2904_CR13","doi-asserted-by":"crossref","DOI":"10.1038\/s41467-021-23903-5","volume":"12","author":"M De Risi","year":"2021","unstructured":"De Risi M, Tufano M, Alvino FG, Ferraro MG, Torromino G, Gigante Y, et al. Altered heparan sulfate metabolism during development triggers dopamine-dependent autistic-behaviours in models of lysosomal storage disorders. Nat Commun. 2021;12:3495.","journal-title":"Nat Commun"},{"key":"2904_CR14","doi-asserted-by":"crossref","first-page":"838","DOI":"10.1016\/j.neubiorev.2021.11.012","volume":"132","author":"S Cannon Homaei","year":"2022","unstructured":"Cannon Homaei S, Barone H, Kleppe R, Betari N, Reif A, Haavik J. ADHD symptoms in neurometabolic diseases: underlying mechanisms and clinical implications. Neurosci Biobehav Rev. 2022;132:838\u201356.","journal-title":"Neurosci Biobehav Rev"},{"key":"2904_CR15","doi-asserted-by":"crossref","first-page":"137","DOI":"10.1007\/978-1-4899-2723-1_9","volume":"235","author":"A Barnett","year":"1988","unstructured":"Barnett A, Iorio LC, McQuade R, Chipkin RE. Pharmacological and behavioral effects of D1 dopamine antagonists. Adv Exp Med Biol. 1988;235:137\u201344.","journal-title":"Adv Exp Med Biol"},{"key":"2904_CR16","doi-asserted-by":"crossref","first-page":"e2022059574","DOI":"10.1542\/peds.2022-059574","volume":"151","author":"DL Gilbert","year":"2023","unstructured":"Gilbert DL, Dubow JS, Cunniff TM, Wanaski SP, Atkinson SD, Mahableshwarkar AR. Ecopipam for Tourette syndrome: a randomized trial. Pediatrics. 2023;151:e2022059574.","journal-title":"Pediatrics"},{"key":"2904_CR17","doi-asserted-by":"crossref","first-page":"1272","DOI":"10.1002\/mds.27457","volume":"33","author":"DL Gilbert","year":"2018","unstructured":"Gilbert DL, Murphy TK, Jankovic J, Budman CL, Black KJ, Kurlan RM, et al. Ecopipam, a D1 receptor antagonist, for treatment of tourette syndrome in children: a randomized, placebo-controlled crossover study. Mov Disord. 2018;33:1272\u201380.","journal-title":"Mov Disord"},{"key":"2904_CR18","doi-asserted-by":"crossref","first-page":"160","DOI":"10.1016\/j.ymgme.2016.04.012","volume":"118","author":"T Khasnavis","year":"2016","unstructured":"Khasnavis T, Torres RJ, Sommerfeld B, Puig JG, Chipkin R, Jinnah HA. A double-blind, placebo-controlled, crossover trial of the selective dopamine D1 receptor antagonist ecopipam in patients with Lesch-Nyhan disease. Mol Genet Metab. 2016;118:160\u20136.","journal-title":"Mol Genet Metab"},{"key":"2904_CR19","doi-asserted-by":"crossref","first-page":"3217","DOI":"10.1007\/s00213-017-4703-9","volume":"234","author":"Y Hara","year":"2017","unstructured":"Hara Y, Ago Y, Taruta A, Hasebe S, Kawase H, Tanabe W, et al. Risperidone and aripiprazole alleviate prenatal valproic acid-induced abnormalities in behaviors and dendritic spine density in mice. Psychopharmacology. 2017;234:3217\u201328.","journal-title":"Psychopharmacology"},{"key":"2904_CR20","doi-asserted-by":"crossref","first-page":"976","DOI":"10.1038\/npp.2009.201","volume":"35","author":"JL Silverman","year":"2010","unstructured":"Silverman JL, Tolu SS, Barkan CL, Crawley JN. Repetitive self-grooming behavior in the BTBR mouse model of autism is blocked by the mGluR5 antagonist MPEP. Neuropsychopharmacology. 2010;35:976\u201389.","journal-title":"Neuropsychopharmacology"},{"key":"2904_CR21","doi-asserted-by":"crossref","first-page":"128","DOI":"10.1007\/BF02246184","volume":"120","author":"DC Hoffman","year":"1995","unstructured":"Hoffman DC, Donovan H. Catalepsy as a rodent model for detecting antipsychotic drugs with extrapyramidal side effect liability. Psychopharmacology. 1995;120:128\u201333.","journal-title":"Psychopharmacology"},{"key":"2904_CR22","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1038\/s41598-021-99269-x","volume":"12","author":"SS Harris","year":"2022","unstructured":"Harris SS, Green SM, Kumar M, Urs NM. A role for cortical dopamine in the paradoxical calming effects of psychostimulants. Sci Rep. 2022;12:1\u20139.","journal-title":"Sci Rep"},{"key":"2904_CR23","doi-asserted-by":"crossref","first-page":"1741","DOI":"10.2147\/NDT.S130444","volume":"13","author":"M Huss","year":"2017","unstructured":"Huss M, Duhan P, Gandhi P, Chen CW, Spannhuth C, Kumar V. Methylphenidate dose optimization for ADHD treatment: review of safety, efficacy, and clinical necessity. Neuropsychiatr Dis Treat. 2017;13:1741\u201351.","journal-title":"Neuropsychiatr Dis Treat"},{"key":"2904_CR24","doi-asserted-by":"crossref","first-page":"112","DOI":"10.15252\/emmm.201606965","volume":"9","author":"I Sambri","year":"2017","unstructured":"Sambri I, D\u2019Alessio R, Ezhova Y, Giuliano T, Sorrentino NC, Cacace V, et al. Lysosomal dysfunction disrupts presynaptic maintenance and restoration of presynaptic function prevents neurodegeneration in lysosomal storage diseases. EMBO Mol Med. 2017;9:112\u201332.","journal-title":"EMBO Mol Med"},{"key":"2904_CR25","doi-asserted-by":"crossref","first-page":"1167","DOI":"10.1016\/j.ymthe.2020.02.005","volume":"28","author":"A Monaco","year":"2020","unstructured":"Monaco A, Maffia V, Sorrentino NC, Sambri I, Ezhova Y, Giuliano T, et al. The amyloid inhibitor CLR01 relieves autophagy and ameliorates neuropathology in a severe lysosomal storage disease. Mol Ther. 2020;28:1167\u201376.","journal-title":"Mol Ther"},{"key":"2904_CR26","doi-asserted-by":"crossref","first-page":"1432","DOI":"10.1016\/j.ymthe.2022.01.037","volume":"30","author":"A Capuozzo","year":"2022","unstructured":"Capuozzo A, Montefusco S, Cacace V, Sofia M, Esposito A, Napolitano G, et al. Fluoxetine ameliorates mucopolysaccharidosis type IIIA. Mol Ther. 2022;30:1432\u201350.","journal-title":"Mol Ther"},{"key":"2904_CR27","doi-asserted-by":"crossref","first-page":"455","DOI":"10.1016\/0028-3908(86)90168-1","volume":"25","author":"BS Starr","year":"1986","unstructured":"Starr BS, Starr MS. Differential effects of dopamine D1 and D2 agonists and antagonists on velocity of movement, rearing and grooming in the mouse: implications for the roles of D1 and D2 receptors. Neuropharmacology. 1986;25:455\u201363.","journal-title":"Neuropharmacology"},{"key":"2904_CR28","doi-asserted-by":"crossref","first-page":"311","DOI":"10.1016\/S0892-0362(03)00009-6","volume":"25","author":"S Sobrian","year":"2003","unstructured":"Sobrian S, Jones BL, Varghese S, Holson R. Behavioral response profiles following drug challenge with dopamine receptor subtype agonists and antagonists in developing rat. Neurotoxicol Teratol. 2003;25:311\u201328.","journal-title":"Neurotoxicol Teratol"},{"key":"2904_CR29","doi-asserted-by":"crossref","first-page":"661","DOI":"10.1017\/S1461145712000569","volume":"16","author":"MJ Luque-Rojas","year":"2013","unstructured":"Luque-Rojas MJ, Galeano P, Su\u00e1rez J, Araos P, Sant\u00edn LJ, De Fonseca FR, et al. Hyperactivity induced by the dopamine D2\/D3 receptor agonist quinpirole is attenuated by inhibitors of endocannabinoid degradation in mice. Int J Neuropsychopharmacol. 2013;16:661\u201376.","journal-title":"Int J Neuropsychopharmacol"},{"key":"2904_CR30","doi-asserted-by":"crossref","first-page":"197","DOI":"10.1016\/j.bbr.2018.10.041","volume":"359","author":"L Olivito","year":"2019","unstructured":"Olivito L, De Risi M, Russo F, De Leonibus E. Effects of pharmacological inhibition of dopamine receptors on memory load capacity. Behav Brain Res. 2019;359:197\u2013205.","journal-title":"Behav Brain Res"},{"key":"2904_CR31","doi-asserted-by":"crossref","first-page":"211","DOI":"10.1101\/lm.025213.111","volume":"19","author":"S Sannino","year":"2012","unstructured":"Sannino S, Russo F, Torromino G, Pendolino V, Calabresi P, De Leonibus E. Role of the dorsal hippocampus in object memory load. Learn Mem. 2012;19:211\u20138.","journal-title":"Learn Mem"},{"key":"2904_CR32","doi-asserted-by":"crossref","first-page":"403","DOI":"10.1136\/adc.69.3.403","volume":"69","author":"MA Clearly","year":"1993","unstructured":"Clearly MA, Wraith JE. Management of mucopolysaccharidosis type III. Arch Dis Child. 1993;69:403\u20136.","journal-title":"Arch Dis Child"},{"key":"2904_CR33","doi-asserted-by":"crossref","first-page":"17631","DOI":"10.18632\/oncotarget.7268","volume":"7","author":"A Belkhiri","year":"2016","unstructured":"Belkhiri A, Zhu S, El-Rifai W. DARPP-32: From neurotransmission to cancer. Oncotarget. 2016;7:17631\u201340.","journal-title":"Oncotarget"},{"key":"2904_CR34","doi-asserted-by":"crossref","first-page":"1856","DOI":"10.1073\/pnas.97.4.1856","volume":"97","author":"P Svenningsson","year":"2000","unstructured":"Svenningsson P, Lindskog M, Ledent C, Parmentier M, Greengard P, Fredholm BB, et al. Regulation of the phosphorylation of the dopamine-and cAMP-regulated phosphoprotein of 32 kDa in vivo by dopamine D1, dopamine D2, and adenosine A2A receptors. Proc Natl Acad Sci USA. 2000;97:1856\u201360.","journal-title":"Proc Natl Acad Sci USA"},{"key":"2904_CR35","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1016\/0091-3057(93)90079-9","volume":"45","author":"R Corbett","year":"1993","unstructured":"Corbett R, Hartman H, Kerman LL, Woods AT, Strupczewski JT, Helsley GC, et al. Effects of atypical antipsychotic agents on social behavior in rodents. Pharmacol Biochem Behav. 1993;45:9\u201317.","journal-title":"Pharmacol Biochem Behav"},{"key":"2904_CR36","first-page":"0322","volume":"2010","author":"J Parr","year":"2010","unstructured":"Parr J. Autism. BMJ Clin Evid. 2010;2010:0322.","journal-title":"BMJ Clin Evid"},{"key":"2904_CR37","doi-asserted-by":"crossref","first-page":"1142","DOI":"10.1176\/appi.ajp.162.6.1142","volume":"162","author":"CJ McDougle","year":"2005","unstructured":"McDougle CJ, Scahill L, Aman MG, McCracken JT, Tierney E, Davies M, et al. Risperidone for the core symptom domains of autism: results from the study by the Autism network of the research units on pediatric psychopharmacology. Am J Psychiatry. 2005;162:1142\u20138.","journal-title":"Am J Psychiatry"},{"key":"2904_CR38","doi-asserted-by":"crossref","DOI":"10.1016\/j.neuropharm.2019.107743","volume":"158","author":"T Gener","year":"2019","unstructured":"Gener T, Tauste-Campo A, Alemany-Gonz\u00e1lez M, Nebot P, Delgado-Sallent C, Chanovas J, et al. Serotonin 5-HT1A, 5-HT2A and dopamine D2 receptors strongly influence prefronto-hippocampal neural networks in alert mice: contribution to the actions of risperidone. Neuropharmacology. 2019;158:107743.","journal-title":"Neuropharmacology"},{"key":"2904_CR39","doi-asserted-by":"crossref","first-page":"553","DOI":"10.1016\/0091-3057(94)90158-9","volume":"47","author":"T Sumiyoshi","year":"1994","unstructured":"Sumiyoshi T, Kido H, Sakamoto H, Urasaki K, Suzuki K, Yamaguchi N, et al. In vivo dopamine-D2 and serotonin-5-HT2 receptor binding study of risperidone and haloperidol. Pharmacol Biochem Behav. 1994;47:553\u20137.","journal-title":"Pharmacol Biochem Behav."},{"key":"2904_CR40","doi-asserted-by":"crossref","first-page":"3101","DOI":"10.1021\/acschemneuro.8b00661","volume":"10","author":"R Depoort\u00e8re","year":"2019","unstructured":"Depoort\u00e8re R, Bardin L, Varney MA, Newman-Tancredi A. Serotonin 5-HT1A receptor biased agonists display differential anxiolytic activity in a rat social interaction model. ACS Chem Neurosci. 2019;10:3101\u20137.","journal-title":"ACS Chem Neurosci"},{"key":"2904_CR41","doi-asserted-by":"crossref","unstructured":"Millichap JG. Etiologic classification of attention-deficit\/hyperactivity disorder. Pediatrics. 2008;121:e358\u201365.","DOI":"10.1542\/peds.2007-1332"},{"key":"2904_CR42","doi-asserted-by":"crossref","first-page":"2276","DOI":"10.1093\/hmg\/ddl152","volume":"15","author":"D Li","year":"2006","unstructured":"Li D, Sham PC, Owen MJ, He L. Meta-analysis shows significant association between dopamine system genes and attention deficit hyperactivity disorder (ADHD). Hum Mol Genet. 2006;15:2276\u201384.","journal-title":"Hum Mol Genet"},{"key":"2904_CR43","doi-asserted-by":"crossref","first-page":"562","DOI":"10.1038\/s41380-018-0070-0","volume":"24","author":"SV Faraone","year":"2019","unstructured":"Faraone SV, Larsson H. Genetics of attention deficit hyperactivity disorder. Mol Psychiatry. 2019;24:562\u201375.","journal-title":"Mol Psychiatry"},{"key":"2904_CR44","doi-asserted-by":"crossref","first-page":"57","DOI":"10.1177\/070674370200601S07","volume":"6","author":"JL Rapoport","year":"2002","unstructured":"Rapoport JL, Inoff-Germain G. Responses to methylphenidate in Attention-Deficit\/Hyperactivity disorder and normal children: update 2002. J Atten Disord. 2002;6:57\u201360.","journal-title":"J Atten Disord"},{"key":"2904_CR45","first-page":"353","volume":"3","author":"C Bodey","year":"2011","unstructured":"Bodey C. Effectiveness and tolerability of methylphenidate in children and adolescents with attention deficit hyperactivity disorder. Clin Med Insights Ther. 2011;3:353\u201363.","journal-title":"Clin Med Insights Ther"},{"key":"2904_CR46","doi-asserted-by":"crossref","first-page":"386","DOI":"10.1038\/sj.mp.4000421","volume":"3","author":"P Seeman","year":"1998","unstructured":"Seeman P, Madras BK. Anti-hyperactivity medication: methylphenidate and amphetamine. Mol Psychiatry. 1998;3:386\u201396.","journal-title":"Mol Psychiatry"},{"key":"2904_CR47","doi-asserted-by":"crossref","first-page":"20140214","DOI":"10.1098\/rstb.2014.0214","volume":"370","author":"BJ Sahakian","year":"2015","unstructured":"Sahakian BJ, Bruhl AB, Cook J, Killikelly C, Savulich G, Piercy T, et al. The impact of neuroscience on society: cognitive enhancement in neuropsychiatric disorders and in healthy people. Philos Trans R Soc B Biol Sci. 2015;370:20140214.","journal-title":"Philos Trans R Soc B Biol Sci"},{"key":"2904_CR48","doi-asserted-by":"crossref","first-page":"143","DOI":"10.1016\/j.pbb.2015.01.005","volume":"131","author":"PK Thanos","year":"2015","unstructured":"Thanos PK, Robison LS, Steier J, Hwang YF, Cooper T, Swanson JM, et al. A pharmacokinetic model of oral methylphenidate in the rat and effects on behavior. Pharmacol Biochem Behav. 2015;131:143\u201353.","journal-title":"Pharmacol Biochem Behav"},{"key":"2904_CR49","doi-asserted-by":"crossref","first-page":"259","DOI":"10.1111\/j.1471-4159.2010.06750.x","volume":"114","author":"K Koda","year":"2010","unstructured":"Koda K, Ago Y, Cong Y, Kita Y, Takuma K, Matsuda T. Effects of acute and chronic administration of atomoxetine and methylphenidate on extracellular levels of noradrenaline, dopamine and serotonin in the prefrontal cortex and striatum of mice. J Neurochem. 2010;114:259\u201370.","journal-title":"J Neurochem"},{"key":"2904_CR50","doi-asserted-by":"crossref","first-page":"2978","DOI":"10.1093\/cercor\/bhy164","volume":"29","author":"C Ramon-Duaso","year":"2019","unstructured":"Ramon-Duaso C, Gener T, Consegal M, Fern\u00e1ndez-Avil\u00e9s C, Gallego JJ, Castarlenas L, et al. Methylphenidate attenuates the cognitive and mood alterations observed in Mbnl2 knockout mice and reduces microglia overexpression. Cereb Cortex. 2019;29:2978\u201397.","journal-title":"Cereb Cortex"},{"key":"2904_CR51","doi-asserted-by":"crossref","first-page":"e447","DOI":"10.1038\/tp.2014.82","volume":"4","author":"S Aga-Mizrachi","year":"2014","unstructured":"Aga-Mizrachi S, Cymerblit-Sabba A, Gurman O, Balan A, Shwam G, Deshe R, et al. Methylphenidate and desipramine combined treatment improves PTSD symptomatology in a rat model. Transl Psychiatry. 2014;4:e447\u20139.","journal-title":"Transl Psychiatry"},{"key":"2904_CR52","doi-asserted-by":"crossref","first-page":"1093","DOI":"10.1016\/S0022-3565(25)13263-1","volume":"247","author":"RE Chipkin","year":"1988","unstructured":"Chipkin RE, Iorio LC, Coffin VL, McQuade RD, Berger JG, Barnett A. Pharmacological profile of SCH39166: a dopamine D1 selective benzonaphthazepine with potential antipsychotic activity. J Pharmacol Exp Ther. 1988;247:1093\u2013102.","journal-title":"J Pharmacol Exp Ther"},{"key":"2904_CR53","doi-asserted-by":"crossref","first-page":"389","DOI":"10.1002\/ddr.430260403","volume":"26","author":"CE Tedford","year":"1992","unstructured":"Tedford CE, Ruperto VB, Coffin VL, Cohen M, Libonati M, Barnett A. SCH 39166, a novel dopamine D1 receptor antagonist: In vitro investigation of its glucuronidation and potential species differences. Drug Dev Res. 1992;26:389\u2013403.","journal-title":"Drug Dev Res"},{"key":"2904_CR54","doi-asserted-by":"crossref","unstructured":"De Risi M, Cavezza D, Torromino G, Capalbo A, Cundin X, Di Martino R, et al. Cortico-Striatal circuit mechanisms drive the effects of D1 dopamine agonists on memory capacity in mice through cAMP\/PKA Signaling. Nat Commun. 2024; in press.","DOI":"10.1038\/s41467-025-57788-5"},{"key":"2904_CR55","doi-asserted-by":"crossref","first-page":"1417","DOI":"10.1038\/s41593-023-01390-9","volume":"26","author":"S Yun","year":"2023","unstructured":"Yun S, Yang B, Anair JD, Martin MM, Fleps SW, Pamukcu A, et al. Antipsychotic drug efficacy correlates with the modulation of D1 rather than D2 receptor-expressing striatal projection neurons. Nat Neurosci. 2023;26:1417\u201328.","journal-title":"Nat Neurosci"},{"key":"2904_CR56","doi-asserted-by":"crossref","first-page":"e25717","DOI":"10.1371\/journal.pone.0025717","volume":"6","author":"A Langford-Smith","year":"2011","unstructured":"Langford-Smith A, Langford-Smith KJ, Jones SA, Wynn RF, Wraith JE, Wilkinson FL, et al. Female mucopolysaccharidosis IIIA mice exhibit hyperactivity and a reduced sense of danger in the open field test. PLoS One. 2011;6:e25717.","journal-title":"PLoS One"},{"key":"2904_CR57","doi-asserted-by":"crossref","first-page":"675","DOI":"10.1002\/emmm.201202083","volume":"5","author":"NC Sorrentino","year":"2013","unstructured":"Sorrentino NC, D\u2019Orsi L, Sambri I, Nusco E, Monaco C, Spampanato C, et al. A highly secreted sulphamidase engineered to cross the blood-brain barrier corrects brain lesions of mice with mucopolysaccharidoses type IIIA. EMBO Mol Med. 2013;5:675\u201390.","journal-title":"EMBO Mol Med"},{"key":"2904_CR58","doi-asserted-by":"crossref","first-page":"1946","DOI":"10.1046\/j.1460-9568.1998.00204.x","volume":"10","author":"P Robledo","year":"1998","unstructured":"Robledo P. Effects of lesions of the nucleus basalis magnocellularis on the acquisition of cocaine self-administration in rats. Eur J Neurosci. 1998;10:1946\u201355.","journal-title":"Eur J Neurosci"},{"key":"2904_CR59","doi-asserted-by":"crossref","DOI":"10.1111\/acel.13189","volume":"19","author":"M De Risi","year":"2020","unstructured":"De Risi M, Torromino G, Tufano M, Moriceau S, Pignataro A, Rivagorda M, et al. Mechanisms by which autophagy regulates memory capacity in ageing. Aging Cell. 2020;19:e13189.","journal-title":"Aging Cell"}],"container-title":["Molecular Psychiatry"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41380-025-02904-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41380-025-02904-6","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41380-025-02904-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,6,23]],"date-time":"2025-06-23T18:02:33Z","timestamp":1750701753000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41380-025-02904-6"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,1,26]]},"references-count":59,"journal-issue":{"issue":"7","published-print":{"date-parts":[[2025,7]]}},"alternative-id":["2904"],"URL":"https:\/\/doi.org\/10.1038\/s41380-025-02904-6","relation":{},"ISSN":["1359-4184","1476-5578"],"issn-type":[{"type":"print","value":"1359-4184"},{"type":"electronic","value":"1476-5578"}],"subject":[],"published":{"date-parts":[[2025,1,26]]},"assertion":[{"value":"26 April 2024","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"11 December 2024","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"20 January 2025","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"26 January 2025","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The authors declare no competing interests.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}]}}